Omega Therapeutics Secures $230M in Series B to Transform Epigenomic mRNA Medicine Development

Omega Therapeutics is excited to announce a major milestone in our journey towards revolutionizing precision epigenomic medicine. We have successfully raised $230,000,000 in our latest funding round, a robust investment that underscores the confidence and enthusiasm of our partners in our innovative approach. As a clinical-stage biotechnology company, Omega Therapeutics stands at the forefront of a promising new era in medical science. Utilizing our groundbreaking OMEGA platform, we harness the power of mRNA as programmable epigenomic medicines—pioneering the systematic control of gene expression that governs every aspect of life, from cell genesis to cell death. The funds raised will be directed towards accelerating our ambitious research and development initiatives, powering our engineered modular mRNA medicines, known as Omega Epigenomic Controllers™, to new heights. These precision tools are designed to target specific intervention points at mapped and validated DNA-sequence-based epigenomic loci, enabling the durable modulation of one or multiple genes. Our efforts are focused on correcting aberrant gene expression and tackling the root causes of a diverse array of diseases without altering native nucleic acid sequences. With a broad pipeline that spans oncology, regenerative medicine, immunology, and select monogenic diseases, the newly secured capital will be instrumental in advancing our clinical programs, expanding our research infrastructure, and fostering strategic collaborations. This infusion of capital marks a significant step toward our goal to offer unprecedented precision in disease treatment and ultimately improve patient outcomes worldwide. We look forward to leveraging this funding to propel Omega Therapeutics into its next phase of innovation and therapeutic discovery.